Trial Profile

A MULTICENTER, OPEN LABEL, RANDOMIZED PHASE II STUDY COMPARING DARATUMUMAB combined with BORTEZOMIB-CYCLOPHOSPHAMIDE- DEXAMETHASONE (Dara-VCd) VERSUS THE ASSOCIATION OF BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE (VTd) AS PRE TRANSPLANT INDUCTION AND POST TRANSPLANT CONSOLIDATION, BOTH FOLLOWED BY A MAINTENANCE PHASE WITH IXAZOMIB ALONE OR IN COMBINATION WITH DARATUMUMAB, IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) YOUNG PATIENTS eligible for AUTOLOGOUS STEM CELL TRANSPLANTATION

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 23 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bortezomib (Primary) ; Daratumumab (Primary) ; Daratumumab (Primary) ; Ixazomib (Primary) ; Cyclophosphamide; Dexamethasone; Thalidomide
Indications Multiple myeloma
Focus Therapeutic Use
Acronyms DaraVCd

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com